Zacks estimated an EPS of $1 for Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN)

(NASDAQ:CATB) to Outperform with a price target of $27.

Recent session action on shares of Catabasis Pharmaceuticals, Inc.

Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) topped its 52-week high price target of 0.43 on Mar 10, 2017.

Sell-side analysts are offering a consensus "Buy" rating on shares of Catabasis Pharmaceuticals, Inc. Analysts have a mean recommendation of 2.50 on this stock (A rating of less than 2 means buy, "hold" within the 3 range, "sell" within the 4 range, and "strong sell" within the 5 range). (NYSEMKT:RNN) a rating of 1 on a scale of 1 to 5. This showed the surprise of 133.3% in the last quarter earnings.

The quarterly dividend payment on the Series E Preferred Stock will be $0.65625 per share, which is equivalent to an annualized 10.50% per share, based on the $25.00 per share stated liquidation preference, accruing from January 1, 2017 through March 31, 2017. Stock has got OUTPERFORM rating from 1 analyst of Thomson Reuters, 2 analysts given HOLD rating to the stock and 0 given UNDERPERFORM rating. These analysts have also projected a Low Estimate of $-0.03/share and a High Estimate of $0/share. As of writing, MRV Communications, Inc.'s RSI stands at 75.47.

The stock as of last trading session moved 253.23% up from its 52 week low and was 4.33% above its 52 week high. The company has a 1 Year high price target of $6.9.

The stock has recorded a 20-day Moving Average of 52.21% and the 50-Day Moving Average is 90.2%.The 200 Day SMA reached 73.11% Rexahn Pharmaceuticals, Inc. The stock has moved up across its 50-day moving average of $0.2229.

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) is now showing its ROA (Return on Assets) of -69.6%. The Return on Assets stands at -41.4%, Return on Equity shows -55.3% and Return on Investment value is 0%. The stock has a weekly performance of 7.44 percent and is 146.06 percent year-to-date as of the recent close. The Stock now has a Weekly Volatility of 16.17% and Monthly Volatility of 14.24%. The correct version of this piece can be viewed at https://www.chaffeybreeze.com/2017/03/14/catabasis-pharmaceuticals-inc-catb-scheduled-to-post-earnings-on-thursday.html. (NASDAQ:CATB) is 98.18. The Average Volume (3 months) is 605.29 Million. During the past three month period the stock surged 179.85% and increased 77.38% in past six month.

Company has reported several Insider transactions to the SEC, on Jan 12, 2015, Tae Heum Jeong (Chief Financial Officer) sold 317,272 shares at 0.91 per share price.On Jan 12, 2015, Chang Ho Ahn (director) sold 314,656 shares at 0.91 per share price. The stock is showing its Operating Margin of 0 percent.

Recommended News

We are pleased to provide this opportunity to share information, experiences and observations about what's in the news.
Some of the comments may be reprinted elsewhere in the site or in the newspaper.
Thank you for taking the time to offer your thoughts.